Table 1 Quantification of tumor class in VP16;Pparg controls and K5VP16;Pparg mutants.
From: Pparg signaling controls bladder cancer subtype and immune exclusion
Time point | Sample | No. of luminal lesions | No. of basal lesions | Time point | Sample | No. of luminal lesions | No. of basal lesions | ||
|---|---|---|---|---|---|---|---|---|---|
Luminal only | Luminal with basal bottom | Â | Luminal only | Luminal with basal bottom | Â | ||||
4 Months K5VP16;Pparg | Het 72 | 5 | 1 | 2 | 4 months control | WT 5 | 0 | 0 | 2 |
Het 74 | 8 | 1 | 1 | WT 3 | 0 | 0 | 5 | ||
Het 51 | 6 | 3 | 6 | WT 88 | 0 | 0 | 1 | ||
Het 1 | 18 | 4 | 4 | WT 54 | 0 | 0 | 3 | ||
Het 53 | 2 | 4 | 3 | WT 55 | 0 | 0 | 1 | ||
Het 56 | 1 | 0 | 1 | WT 2 | 0 | 0 | 3 | ||
Het 57 | 3 | 0 | 3 | WT 83 | 0 | 0 | 5 | ||
Het70 | 5 | 1 | 4 | WT 20 | 0 | 0 | 2 | ||
Het 9 | 1 | 0 | 2 | WT 19 | 0 | 0 | 1 | ||
Het 75 | 6 | 1 | 2 | WT 56 | 0 | 0 | 2 | ||
Total | 55 | 15 | 28 | Total | 0 | 0 | 25 | ||
3 Months K5VP16;Pparg | Het 44 | 8 | 1 | 3 | 3 months control | WT61 | 0 | 0 | 3 |
Het 62 | 6 | 0 | 3 | WT58 | 0 | 0 | 4 | ||
Het 50 | 2 | 0 | 0 | WT59 | 0 | 0 | 4 | ||
Het 4 | 7 | 0 | 1 | WT 5 | 0 | 0 | 4 | ||
Het 7 | 4 | 0 | 3 | WT81 | 0 | 0 | 3 | ||
| Â | Â | Â | Â | WT22 | 0 | 0 | 2 | ||
Total | 27 | 1 | 10 | Total | 0 | 0 | 20 | ||
2 Months K5VP16;Pparg | Het70 | 4 | 0 | 0 | 2 months control | WT50 | 0 | 0 | 1 |
Het 56 | 1 | 0 | 0 | WT49 | 0 | 0 | 1 | ||
Het 62 | 2 | 0 | 0 | WT40 | 0 | 0 | 2 | ||
Total | 7 | 0 | 0 | Total | 0 | 0 | 4 | ||
1 Month K5VP16;Pparg | Het 8 | 0 | 0 | 0 | 1 month control | Â | Â | Â | Â |
WT 66 | 0 | 0 | 0 | Â | Â | Â | Â | ||
Het 50 | 0 | 0 | 0 | WT 70 | 0 | 0 | 0 | ||
Het 10 | 0 | 0 | 0 | WT 79 | 0 | 0 | 0 | ||
Total | 0 | 0 | 0 | Total | 0 | 0 | 28 | ||
